Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2026)

Intellia Therapeutics (NTLA) has 7 years of Long-Term Investments data on file, last reported at $10.1 million in Q1 2026.

• On a quarterly basis, Long-Term Investments rose 347.24% year-over-year to $10.1 million in Q1 2026; TTM through Mar 2026 was $10.1 million, a 347.24% increase from a year earlier, with the FY2025 full-year figure at $11.4 million, down 95.61% from the prior year.
• Long-Term Investments for Q1 2026 stood at $10.1 million, down from $11.4 million in the prior quarter.
• Over the last five years, Long-Term Investments for NTLA reached as high as $260.2 million in Q4 2024 and fell as low as $2.3 million in Q1 2025.
• Historically, Long-Term Investments has averaged $66.5 million across 5 years, with a median of $32.6 million in 2022.
• Across the five-year window, Long-Term Investments jumped 2502.15% in 2024 and plunged 98.6% in 2025, its largest moves.
• Year by year, Long-Term Investments stood at $32.5 million in 2022, then slumped by 69.19% to $10.0 million in 2023, then soared by 2502.15% to $260.2 million in 2024, then sank by 95.61% to $11.4 million in 2025, then slipped by 11.33% to $10.1 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $10.1 million in Q1 2026, $11.4 million in Q4 2025, and $22.5 million in Q3 2025.